REGULATED PRESS RELEASE published on 07/07/2025 at 07:00, 8 months 15 days ago Obesity: Biophytis Charts Its Course Toward a Booming Market Biophy.s SA is focusing on developing transformative therapies for obesity, sarcopenia, and longevity by addressing muscle loss with its lead drug BIO101. The company's strategic positioning targets the expanding obesity market BIO101 Obesity Market Opportunity Muscle Loss Biophy.s SA
BRIEF published on 07/03/2025 at 07:05, 8 months 19 days ago Biophytis Showcases Innovations at BIO International 2025 Biophytis Precision Medicine Longevity Sarcopenia Obesity Therapy
BRIEF published on 07/03/2025 at 07:05, 8 months 19 days ago Biophytis : Avancées Thérapeutiques Présentées à la BIO International 2025 Biophytis Innovations Santé Thérapies Convention BIO 2025
REGULATED PRESS RELEASE published on 07/03/2025 at 07:00, 8 months 19 days ago Biophythis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025 Biophytis highlights innovations in obesity, muscle health, and longevity at BIO International 2025, showcasing therapies targeting key health challenges. Strategic partnerships post-conference aim to accelerate therapies' global impact Innovations Longevity Obesity Muscle Health Biophy(s
REGULATED PRESS RELEASE published on 07/03/2025 at 07:00, 8 months 19 days ago Biophytis Propulse l’Innovation dans l’Obésité, la Santé Musculaire et la Longévité à la BIO International 2025 BiophyHs SA présente ses avancées dans l'obésité, la sarcopénie et la longévité à la BIO Interna(onal 2025, soulignant ses thérapies innovantes et partenariats stratégiques pour le développement mondial Longévité Sarcopénie Obésité BiophyHs SA BIO InternaHonal 2025
PRESS RELEASE published on 07/03/2025 at 06:59, 8 months 19 days ago Biophytis Propulse l’Innovation dans l’Obésité, la Santé Musculaire et la Longévité à la BIO International 2025 BiophyHs annonce son succès à la BIO International Convention 2025, présentant des avancées en obésité, sarcopénie et longévité, avec des partenariats stratégiques post-conférence Longévité Sarcopénie Obésité BIO International Convention 2025 BiophyHs
BRIEF published on 06/30/2025 at 22:35, 8 months 22 days ago Biophytis reporte la publication de ses comptes annuels Biophytis Biotechnologie Comptes Annuels Recherche Clinique Publication Retardée
BRIEF published on 06/30/2025 at 22:35, 8 months 22 days ago Biophytis Delays Publication of 2024 Annual Financial Statements Biophytis Biotechnology Drug Development Annual Accounts Financial Delay
REGULATED PRESS RELEASE published on 06/30/2025 at 22:30, 8 months 22 days ago Information on the Annual Financial Statements Biophytis delays publishing of 2024 annual accounts, aiming for release by July 7. The company focuses on treatments for age-related diseases Financial Statements Biophytis Age-related Diseases 2024 Annual Accounts Clinical-stage Biotechnology Company
REGULATED PRESS RELEASE published on 06/30/2025 at 22:30, 8 months 22 days ago Information sur les comptes annuels Biophytis SA informe qu'elle n'est pas en mesure de publier ses comptes annuels 2024 à la date prévue mais les publiera au plus tard le 07 juillet 2025 Biophytis Développement Biotechnologie Comptes Annuels Maladies Liées À L'âge
Published on 03/20/2026 at 13:30, 2 days 12 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 13 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 13 hours 32 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 3 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 4 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days 4 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 6 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 6 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 7 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 7 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA